Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell leukemia, T-cell prolymphocytic leukemia, bone marrow disorder, cardiovascular disorder, chronic myeloid leukemia, chronic myelomonocytic leukemia, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, plasma cell leukemia, plasma cell neoplasm, prolymphocytic leukemia, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2026-10-07		NCT05823571

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Incyte Corporation	153
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	117

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	United States	8